Core Insights - Bernstein Private Wealth Management has appointed Kim Mustin to lead its Business Owner segment, reflecting the firm's strategic commitment to entrepreneurial clients [1][2] - 75% of Bernstein's Wealth Advisors serve business owners, indicating a strong focus on this client segment [2] - The firm has experienced significant growth, with new business from the Business Owner segment representing over 30% of the total expected for full-year 2025 in Q1 2026 [2] Company Strategy - The appointment of Mustin aims to integrate insights across the business owner ecosystem, providing a holistic approach to wealth planning for founders [2] - Bernstein's strategy includes offering retirement services to mid-sized business owners and private equity firms, enhancing its service offerings [2][4] - The firm has a long history of partnering with business owners, providing support throughout their ownership journey, including transition planning and multigenerational wealth preservation [4] Leadership and Experience - Kim Mustin has over 35 years of experience in financial services and civil service, having joined Bernstein in 2017 [3] - Mustin's leadership is expected to enhance the firm's ability to support clients during critical liquidity events, emphasizing the importance of preparation and strategic decision-making [3] Financial Overview - As of December 31, 2025, Bernstein manages $156 billion in assets under management, showcasing its significant market presence [5] - AllianceBernstein, the parent company, manages over $867 billion in assets, positioning it among the largest investment managers globally [7]

Core Viewpoint - The Ademi Firm is investigating Centessa Pharmaceuticals plc for potential breaches of fiduciary duty and other legal violations related to its transaction with Lilly, focusing on whether shareholders are receiving a fair price [1][4]. Transaction Details - Centessa stockholders will receive $38.00 per share in cash, along with contingent value rights valued up to $9.00 per share, which include milestone payments contingent on FDA approvals for specific treatments [3]. - The contingent value rights include payments of $2.00 upon FDA approval for narcolepsy type 2 treatment, $5.00 for idiopathic hypersomnia approval, and $2.00 for any indication approval before January 1, 2030, with all approvals required within five years of the transaction closing [3]. Board Conduct and Shareholder Rights - The transaction agreement imposes significant penalties on Centessa for accepting competing bids, which raises concerns about the board's fulfillment of fiduciary duties to all shareholders [4]. - The investigation will assess whether the Centessa board is acting in the best interests of shareholders amidst substantial benefits for insiders as part of the change of control arrangements [4].

Group 1 - Ilkka Oyj acquired 1,229 shares at an average price of EUR 4.2054 per share, totaling a cost of EUR 5,168.44 on 31 March 2026 [1] - After the acquisition, Ilkka Oyj holds a total of 143,568 treasury shares [1] Group 2 - Ilkka is a marketing and technology company that provides professional, data, and technology services in digital marketing and communications [2] - The core of Ilkka's business includes the software company Liana, its Swedish subsidiary Ungapped, and other specialized agencies in data-driven sales and marketing, WordPress digital services, and social media marketing [2] - The company employs approximately 330 marketing, technology, and data experts and focuses on international markets, particularly Sweden and emerging markets in the Middle East [2]

Core Viewpoint - Iveco Group N.V. has announced the sale of its Defence business to Leonardo S.p.A., with the informative document regarding this transaction made available on its corporate website [1]. Company Overview - Iveco Group N.V. is a significant player in the automotive industry, rooted in Italian heritage and possessing a strong international presence [2]. - The company emphasizes engineering excellence and innovation, focusing on sustainable mobility and customer-driven technologies [2]. - Iveco Group operates five brands: IVECO (commercial vehicles), FPT (powertrain technologies), IVECO BUS and HEULIEZ (mass transit solutions), and IVECO CAPITAL (financing arm) [2]. - The company employs 33,000 people and has 16 industrial sites along with 22 R&D centers [2].

Core Viewpoint - JLL Income Property Trust has announced a shift from quarterly to monthly distributions for its stockholders, declaring three consecutive monthly distributions of $0.0525 per share for the second quarter of 2026, aimed at providing faster and more frequent cash flow to investors [1][4]. Distribution Details - The monthly distributions of $0.0525 per share will be payable in April, May, and June 2026 to stockholders of record as of April 23, May 22, and June 23, 2026, respectively [2]. - The annualized gross distribution of $0.63 per share represents a distribution rate of approximately 5.6% based on a NAV per share of $11.23 as of the date of approval [2]. Changes in Dividend Declaration - The Board of Directors revoked the previous quarterly dividend declaration of $0.1575 for the quarter commencing April 1 and ending June 30, replacing it with the new monthly distribution structure [3]. Management's Perspective - The President and CEO of JLL Income Property Trust emphasized that the new monthly distribution approach is designed to enhance the reliability of income for stockholders, building on a track record of 57 consecutive quarterly distributions over 13 years [4].

Core Viewpoint - Kering and L'Oréal have finalized their strategic alliance in the beauty sector, which includes L'Oréal's acquisition of Kering Beauté and the signing of beauty and fragrance licenses for Kering's iconic brands [2][3]. Group 1: Strategic Partnership Details - The agreement confirms L'Oréal's acquisition of Kering Beauté, which includes the House of Creed, and establishes beauty and fragrance licenses for Kering's iconic Houses [3]. - The transaction is valued at €4 billion, paid in cash, with L'Oréal also agreeing to pay royalties to Kering for the use of the licensed brands [4]. Group 2: Leadership Statements - Kering's CEO, Luca de Meo, emphasized that the alliance will leverage L'Oréal's expertise to accelerate the development of fragrances and cosmetics for Kering's Houses, enhancing their potential in this category [4]. - L'Oréal's CEO, Nicolas Hieronimus, expressed that this partnership strengthens L'Oréal's position as a leader in beauty and luxury, aiming to unlock growth potential for the iconic brands over the next fifty years [4]. Group 3: Company Background - Kering is a global luxury group with a portfolio that includes brands such as Gucci, Saint Laurent, and Bottega Veneta, generating revenue of €14.7 billion in 2025 and employing 44,000 people [5].

Group 1 - Iveco Group N.V. announced the sale of its Defence business to Leonardo S.p.A. on 18 March 2026, with an Informative Document published on 31 March 2026 [1] - The Informative Document is prepared in accordance with Article 71, paragraph 1, and follows the regulations set by CONSOB [1] - The document is accessible in the Investors section of the Iveco Group corporate website [1] Group 2 - Iveco Group N.V. is a significant player in the automotive industry, emphasizing sustainable mobility and customer-driven technologies [2] - The Group operates five brands: IVECO, FPT, IVECO BUS, HEULIEZ, and IVECO CAPITAL, each leading in their respective sectors [2] - The company employs 33,000 people and has 16 industrial sites along with 22 R&D centres [2]

Company Overview - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy [3] - The company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line [3] - Jupiter's proprietary formulation, JOTROL, has shown improved bioavailability in clinical studies and is central to both its prescription pipeline and consumer products [3] Product Offerings - The prescription pipeline includes a Phase IIa clinical trial for Parkinson's disease and targets other CNS disorders such as Alzheimer's Disease and Friedreich's Ataxia [3] - Nugevia, the consumer longevity product line, features three formulations: PWR (mitochondrial support), MND (cognitive health), and GLO (skin vitality), utilizing the same JOTROL technology [4] - Products are available direct-to-consumer and the company is expanding into practitioner-led channels to leverage the clinical-grade bioavailability of its formulations [4] Conference Participation - Jupiter has been invited to present its clinical and commercial progress at the Emerging Growth Conference on April 2, 2026, at 10:15 AM ET, inviting both individual and institutional investors to attend [1] - An archived webcast of the presentation will be available post-event for those unable to attend live [1][2]

Core Insights - WINFARM reported a strong improvement in its 2025 full-year results, with significant growth in revenue and EBITDA, indicating a positive trajectory for the company [1][4][11] Financial Performance - The consolidated revenue for 2025 reached €146.5 million, marking a 6.1% increase from €138.0 million in 2024 [3][4] - The gross margin improved to 34.4% of revenue, up from 33.5% in 2024, reflecting effective pricing strategies [3][11] - EBITDA surged to €5.3 million, a 3.9 times increase compared to €1.4 million in 2024, with the EBITDA margin rising by 2.6 percentage points to 3.6% [3][13] - The net loss for 2025 decreased to €0.8 million from €3.7 million in 2024, indicating a recovery in financial performance [3][14] Business Segments - The Farming Supplies segment, which constitutes 86% of total revenue, generated €127.2 million, a 4.5% increase, driven by strong sales in the "Hygiene" and "Animal Nutrition" product families [5][4] - The Farming Production segment saw a revenue increase of 19% to €16.6 million, with Asia contributing nearly 40% of this revenue and experiencing a growth rate of 47.3% compared to 2024 [9] - Other activities, including Farming Advisory and Farming Innovation, also reported growth, supported by new sales initiatives [10] Cash Flow and Debt Management - The company generated cash flow of €1.4 million in 2025, a significant turnaround from a negative cash flow of €5.4 million in 2024 [6][17] - WINFARM reduced its net financial debt by €7 million, bringing it down to €29.2 million by the end of 2025 [17] Strategic Outlook - For 2026, WINFARM plans to continue its sales initiatives, particularly focusing on the 30th anniversary of the VITAL brand, which has shown strong growth in key markets [18] - The company aims to maintain operational and financial discipline, which is expected to lead to further increases in EBITDA and continued debt reduction [19]

Core Viewpoint - Ademi LLP is investigating Apellis Pharmaceuticals Inc. for potential breaches of fiduciary duty and other legal violations related to its transaction with Biogen, focusing on whether shareholders are receiving a fair price [1][4]. Transaction Details - Apellis stockholders will receive $41 per share plus a contingent value right, which includes additional payments based on the sales performance of SYFOVRE [3]. - Under the contingent value rights, shareholders could receive $2 per share if SYFOVRE achieves $1.5 billion in annual global net sales between 2027 and 2030, and another $2 per share if it reaches $2 billion in annual sales during the same period. If these thresholds are not met but SYFOVRE achieves $2 billion in sales in 2031, shareholders would receive $4 per share [3]. Board Conduct and Shareholder Rights - The transaction agreement imposes significant penalties on Apellis for accepting competing bids, which raises concerns about the board's fulfillment of fiduciary duties to all shareholders [4]. - Apellis insiders are set to receive substantial benefits as part of the change of control arrangements, further complicating the fairness of the transaction for public shareholders [4].